Key clinical point: Giving an immunomodulator with pegloticase improved outcomes of refractory gout.

Major finding: A total of 19 of 22 patients who received pegloticase with mycophenolate mofetil had serum uric acid levels <6 mg/dL at 12 weeks, compared with 4 of 10 patients assigned to pegloticase and placebo.

Study details: A randomized, placebo-controlled, phase 2 trial in 32 patients with refractory gout.

Disclosures: The study was sponsored by the University of Alabama at Birmingham, with collaboration from the University of Michigan, as well as the National Institute of Arthritis and Musculoskeletal and Skin Diseases and Horizon, which makes pegloticase. Dr. Khanna disclosed grant and research support from Dyve, Selecta, and Sobi, and consulting for Sobi and Horizon. Dr. Dalbeth disclosed relationships with AstraZeneca, AbbVie, Arthrosi, Dyve, Selecta, and Janssen. Dr. Bhana disclosed nonbranded consulting work for Horizon.